STOCKHOLM, Sept. 30, 2024 /PRNewswire/ — As per 30 September 2024, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 356,000,049 shares. All shares are common shares. The total number of votes is 356,000,049. The increase in the number of shares and…
Month: September 2024
Autoliv Retires Repurchased Shares, Decreases Number of Issued Shares
STOCKHOLM, Sept. 30, 2024 /PRNewswire/ — Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announced that as of September 30, 2024, the total number of issued shares of common stock is 83,487,293 of which 78,750,609 shares are outstanding….
Announcement of change in the total number of votes in AB SKF
GOTHENBURG, Sweden, Sept. 30, 2024 /PRNewswire/ — Due to a conversion of shares from Series A to Series B in accordance with AB SKF’s Articles of Association, the Company confirms the following. As per 30 September 2024, there are a total of 455,351,068 shares in AB SKF, out of which…
New number of shares and votes in Sobi
STOCKHOLM, Sept. 30, 2024 /PRNewswire/ — As per 30 September 2024, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 356,000,049 shares. All shares are common shares. The total number of votes is 356,000,049. The increase in the number of shares and…
Alejandro Corominas Menéndez appointed President and CEO of Loomis Europe and Latin America
STOCKHOLM, Sept. 30, 2024 /PRNewswire/ — Alejandro Corominas Menéndez has been appointed President and CEO of Loomis Europe and Latin America as of January 1, 2025. Currently, Alejandro holds the position as Country CEO of Loomis Spain and Regional Vice President for Loomis Europe and…
Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting
OSLO, Norway, Sept. 30, 2024 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international multicenter Phase III clinical study data for its non-surgical treatment candidate Cevira®…
Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting
OSLO, Norway, Sept. 30, 2024 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international multicenter Phase III clinical study data for its non-surgical treatment candidate Cevira®…
Pioneering GeneTree Nano-Crystalline Ceramic Core: Debuting the First High-Capacity, High-Wattage Solution in Vape Industry
SHENZHEN, China, Sept. 30, 2024 /PRNewswire/ — In the realm of novel tobacco products, ceramic atomization technology has long been a driving force for innovation. As industry titans vie for technological supremacy, the capacity and power limitations of ceramic cores have remained…
J.S. Held: Strategisch adviseurs van 65% van de Fortune 100
JERICHO, N.Y., 30 september 2024 /PRNewswire/ — Wereldwijd adviesbureau J.S. Held viert met trots 50 transformerende jaren als strategisch adviseur voor een breed spectrum aan klanten, waaronder 65% van de directieleden van Fortune 100 bedrijven, raden van bestuur en hun financiële…
Pioneering GeneTree Nano-Crystalline Ceramic Core: Debuting the First High-Capacity, High-Wattage Solution in Vape Industry
SHENZHEN, China, Sept. 30, 2024 /PRNewswire/ — In the realm of novel tobacco products, ceramic atomization technology has long been a driving force for innovation. As industry titans vie for technological supremacy, the capacity and power limitations of ceramic cores have remained…
